Related Experiment Video
Updated: May 19, 2026
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Early versus conventional treatment for patent ductus arteriosus in preterm infants
Júlia Candel-Pau1, Ángeles Linde Sillo, Félix Castillo Salinas
1Vall d'Hebron Research Institute, Neonatology Unit, Barcelona, Spain. 38751jcp@comb.es
Insights
Early indomethacin treatment for patent ductus arteriosus (PDA) in high-risk newborns showed no significant differences in safety or efficacy compared to conventional methods. This study evaluated outcomes in a vulnerable infant population.
Area of Science:
- Neonatalogy
- Pediatric Cardiology
- Pharmacology
Background:
- Patent ductus arteriosus (PDA) is common in premature infants.
- Early indomethacin treatment is a new protocol for PDA.
- Conventional treatment is the established approach.
Purpose of the Study:
- To compare the safety and efficacy of early indomethacin treatment versus conventional treatment for PDA.
- To assess outcomes in a high-risk population of newborns.
Main Methods:
- Retrospective cohort study.
- Included 154 newborns with average gestational age of 26.4 weeks and birth weight of 855 g.
- Statistical analysis using SPSS Statistics Pack version 17.0.
Main Results:
- No statistically significant differences were found in clinical features between the two treatment groups.
- Efficacy, morbidity, and mortality results were comparable between early indomethacin and conventional treatment groups.
Conclusions:
- Early indomethacin treatment for PDA in high-risk newborns appears to be as safe and effective as conventional treatment.
- Further research may be warranted to confirm these findings in larger cohorts.
Objective:
After the introduction of a new protocol based on the early treatment with indomethacin for patent ductus arteriosus, the objective of this study was to assess the safety and efficacy of this new practice in comparison with the safety and efficacy of the conventional treatment in a high-risk population.
Study Design:
We conducted a retrospective cohort study including 154 newborns with an average gestational age of 26.4 weeks (1.37 standard deviation) and an average birth weight of 855 g (201.5 standard deviation). A statistically descriptive analysis was performed with SPSS Statistics Pack version 17.0.
Results And Conclusions:
We did not find any statistically significant differences in the clinical features of the two treatment groups, nor in the main efficacy, morbidity, and mortality results.
